

Formulary Adherence Checklist for NICE Technology Appraisals About Medicines



Milton Keynes Health Economy

Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. **Version 5.10. May 2015.**  
All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
<b>2014-15</b>							
<a href="#">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA 338)</a>	31/03/2015	<b>Pomalidomide</b> - not recommended, in combination with dexamethasone, for treating relapsed and refractory multiple myeloma in adults who have had at least 2 previous treatments, including lenalidomide and bortezomib, and whose disease has progressed on the last therapy		x	27/04/2015	27	TA338 - not recommended
<a href="#">Rifaximin for preventing episodes of overt hepatic encephalopathy (TA 337)</a>	31/03/2015	<b>Rifaximin</b> - an option for reducing the recurrence of episodes of overt hepatic encephalopathy	x		27/05/2015	57	CCG Funded. Available in line with NICE recommendation and locally agreed criteria
<a href="#">Empagliflozin in combination therapy for treating type 2 diabetes (TA 336)</a>	31/03/2015	<b>Empagliflozin</b> - an option in combination with other treatments for some patients with type 2 diabetes.	x		27/05/2015	57	CCG Funded. Available in line with NICE recommendation and locally agreed criteria
<a href="#">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA 335)</a>	31/03/2015	<b>Rivaroxaban</b> - an option, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in people who have had an acute coronary syndrome with elevated cardiac biomarkers. Treatment should only be started after careful assessment of bleeding risk and informed discussion between clinician and patient of benefits and risks. Treatment should be reviewed no later than 12 months after starting. Clinicians should regularly reassess the relative benefits and risks of continuing treatment with rivaroxaban and discuss them with the patient.	x		27/05/2015	57	CCG Funded. Available in line with NICE recommendation and locally agreed criteria
<a href="#">Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (TA 334)</a>	28/02/2015	<b>Regorafenib</b> - unable to recommend NHS use because no evidence received from manufacturer		x	25/03/2015	25	TA334 - Terminated
<a href="#">Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA 333)</a>	28/02/2015	<b>Axitinib</b> - an option for treatment of advanced renal cell carcinoma after failure with a first-line tyrosine kinase inhibitor, e.g. sunitinib, or a cytokine.	x		23/03/2015	23	NHS England funded; Axitinib 1mg nd 5mg tablets (Inlyta®) are not funded for routine use at Milton Keynes Hospital; it is not for initiation or routine supply for patients managed at Milton Keynes Hospital; Patient access scheme

Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA 332)	28/02/2015	<b>Sipuleucel-T</b> - not recommended as a treatment for asymptomatic or minimally symptomatic metastatic non-visceral hormone-relapsed prostate cancer when chemotherapy is not yet suitable.		x	23/03/2015	23	TA332 - not recommended
Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA 331)	28/02/2015	<b>Simeprevir</b> - an option, in combination with peginterferon alfa and ribavirin, for treatment of genotypes 1 or 4 chronic hepatitis C.	x		23/03/2015	23	NHS England funded; Simeprevir 150mg capsules (Olysio®) is not funded for routine use at Milton Keynes Hospital; it is not for initiation or routine supply for patients at Milton Keynes Hospital
Sofosbuvir for treating chronic hepatitis C (TA 330)	28/02/2015	<b>Sofosbuvir</b> - an option, in combination with peginterferon alfa and ribavirin, or with ribavirin alone, for the treatment for adults with certain genotypes of chronic hepatitis C.	x		23/03/2015	23	NHS England funded; Sofosbuvir 400mg tablet (Sovaldi®) is not funded for routine use at Milton Keynes Hospital; it is not for initiation or routine supply for patients at Milton Keynes Hospital
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (TA 329)	28/02/2015	<b>Infliximab, adalimumab, golimumab</b> - all options for treatment of moderately to severely active ulcerative colitis in adults after failure of conventional therapy (including a review of TA140 and TA262)	x		23/03/2015	23	CCG Funded; A funding request MUST be made to the CCG if there is any ambiguity regarding prescribing. Used in line with NICE guidance Patient access scheme
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)	31/12/2014	<b>Idelalisib</b> - unable to recommend NHS use because no evidence received from manufacturer		x	23/03/2015	82	TA328 - terminated appraisal
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)	31/12/2014	<b>Dabigatran etexilate</b> - an option for treatment and for secondary prevention of recurrent DVT and PE	x		23/03/2015	82	In line with NICE recommendation and local guidelines pending a full review of the use of NOACs.
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)	30/11/2014	<b>Imatinib</b> - an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery for KIT (CD117)-positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 criteria.	x		28/01/2015	59	NHS England funded; NOT funded for routine use; It is NOT for initiation or routine supply for patients managed by MKHFT.
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)	30/11/2014	<b>Nalmefene</b> - an option for reducing alcohol consumption, for people with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms and who do not require immediate detoxification. Should only be prescribed in conjunction with continuous psychosocial support and be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.	x		28/01/2015	59	For CRI Specialist use only within Milton Keynes Hospital in line with NICE guidance and local pathway
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) (TA323)	30/11/2014	<b>Erythropoiesis-stimulating agents</b> (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) - options for treating anaemia in people with cancer who are having chemotherapy. If different agents are equally suitable, the product with the lowest cost should be used.	x		28/01/2015	59	NHS England funded; NOT funded for routine use; It is NOT for initiation or routine supply for patients managed by MKHFT.

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)	30/09/2014	<b>Lenalidomide</b> - an option for treating transfusion-dependent anaemia caused by low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other options are insufficient or inadequate, with the proviso that the cost of the drug (excluding any related costs) for people who remain on treatment for more than 26 cycles will be met by the company.	x		26/11/2014	57	NHS England funded and will be available in line with NICE recommendations. Patient Access Scheme.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)	31/10/2014	<b>Dabrafenib</b> - an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma only if the manufacturer provides the medicine with the discount agreed in the patient access scheme.	x		26/11/2014	26	NHS England funded; NOT funded for routine use; It is NOT for initiation or routine supply for patients managed by MKHFT.
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)	29/08/2014	<b>Dimethyl fumarate</b> - an option for treating adults with active relapsing-remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years), only if they do not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and the manufacturer provides the medicine with the discount agreed in the patient access scheme.	x		24/09/2014	26	NHS England funded and will be available in line with NICE recommendations. Patient Access Scheme.
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)	31/07/2014	<b>Ipilimumab</b> - an option, within its marketing authorisation, for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.	x		24/09/2014	55	NHS England funded and will be available in line with NICE recommendations. Patient Access Scheme.
Lubiprostone for treating chronic idiopathic constipation (TA318)	31/07/2014	<b>Lubiprostone</b> - an option for adults with chronic idiopathic constipation in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.	x		24/09/2014	55	<i>CCG funded and will be available in line with NICE recommendations</i>
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) (TA317)	31/07/2014	<b>Prasugrel 10mg</b> - an option, in combination with aspirin, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina, non-ST segment elevation myocardial infarction or ST segment elevation myocardial infarction) having primary or delayed percutaneous coronary intervention.	x		31/07/2014	0	
Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)	31/07/2014	<b>Enzalutamide</b> - an option, within its marketing authorisation, for metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy, only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.	x		24/09/2014	55	NHS England funded and will be available in line with NICE recommendations. Patient Access Scheme.
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)	30/06/2014	<b>Canagliflozin</b> - an option in combination with other treatments for some patients with type 2 diabetes.	x		04/07/2014	4	In line with NICE guidance

Psoriatic arthritis (active) - ustekinumab (TA313)	30/05/2014	<b>Ustekinumab</b> - not recommended alone or with methotrexate for adults when the response to previous non-biological disease-modifying antirheumatic drug therapy has been inadequate.	X		30/05/2014	0	TA313 - not recommended
Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)	30/05/2014	<b>Alemtuzumab</b> - an option for adults with active relapsing-remitting multiple sclerosis.	x		04/07/2014		
Multiple myeloma - bortezomib (induction therapy) (TA311)	30/04/2014	<b>Bortezomib</b> - an option, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.	X		28/05/2014	28	High Cost Drug pathway
Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310)	30/04/2014	<b>Afatinib</b> - an option for adults with locally advanced or metastatic non-small-cell lung cancer if they have the EGFR-TK mutation and have not had a EGFR-TK inhibitor previously and the drug is provided at the discount agreed in the patient access scheme.	X		28/05/2014	28	Patient access scheme.
Lung cancer (non small cell, non squamous) - pemetrexed (TA309)	30/04/2014	<b>Pemetrexed</b> - not recommended as maintenance treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer after induction therapy with pemetrexed and cisplatin.	X		28/05/2014	0	TA309 - not recommended
			24	4			
			% "Yes"	% "N/A"	-	Average implement time (days)	
<b>Adherence statistics for 2014-15</b>			89%	15%		<b>38</b>	